Christopher B. Ehrlich, Director at eFFECTOR Therapeutics, Inc. (EFTR), bought 2,000 shares at $4.92 ($10K) on 2022-02-08, disclosed to the SEC on 2022-02-10.
Open-market purchase of $10k EFTR by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.92 | 1,000 | $5K | 50.9% |
| 2 | $4.75 | 1,000 | $5K | 49.1% |
| Total | $4.83 avg | 2,000 | $10K | 100% |
| Filing → |
| EFTR | BUY | 2022-02-22 | $13K | — | Filing → |
| EFTR | BUY | 2022-02-07 | $31K | — | Filing → |
| EFTR | BUY | 2022-01-31 | $27K | — | Filing → |